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INTRODUCTION:
An articular cartilage lesion, notably generated by osteoarthritis (OA),
is initiated partly by the loss of proteoglycan content from the 
extracellular matrix and manifests as pain or disturbed joint function [1].
Strategies that restore the proteoglycan content would be of therapeutic 
benefit to prevent, delay, or even reverse the progression of the lesion.
Numerous clinical and experimental approaches have been widely 
applied [2-4] to relieve the pain or induce healing of the lesion; however 
these require surgical intervention. Orally administrated drugs, if 
available, may revolutionize the treatment of osteoarthritis by allowing 
non-invasive and repeatable treatment. Small chemical compounds are 
able to interact and alter the function of specific proteins that are 
involved in physiological or pathogenic pathways [5]. With the 
advancements in chemical synthesis and high-throughput technologies, 
novel drugs can be swiftly discovered from high throughput screening 
(HTS) of chemical libraries. We hypothesize that chemical compounds 
that are capable of modulating the metabolic pathway of proteoglycans 
would thus affect the proteoglycan level in cartilage. Using progressive 
high-throughput screening processes, this study aims to use a chemical 
genetics approach to identify chemical compounds that can promote the 
proteoglycan production by chondrocytes.
MATERIALS AND METHODS:
The primary HTS started with 50,240 diverse compounds (20 µg/ml) 
from a synthetic chemical library (ChemBridge). Each compound was
plated into individual wells of 384-well plates with the automatic liquid 
handling station (Biomek 2000, Beckman Coulter). Primary 
chondrocytes isolated from porcine costal cartilage by aseptic digestion 
using pronase and collagenase II were then added to each well (30, 000
chondrocytes/cm2). Assay plates were incubated at 37oC in 5% CO2 for 
72 hours. The glycosaminoglycan (GAG) content in the media was 
measured by the dimethylmethylene blue (DMMB) assay at 535 nm 
(reference to 450 nm) [6]. The corresponding metabolic activity was
measured in parallel under similar conditions by the MTT assay at 570
nm (reference to 640 nm). The screening was performed in triplicate.
The DMMB and MTT readouts were normalized with unperturbed 
control (media without addition of any chemical compound). The top 
950 compounds prioritized by the DMMB readouts over the medians
were validated with the secondary HTS. The compounds were re-
arrayed in 96-well plates at a lower concentration (5 µg/ml) and similar 
assays were performed. Positive hits were finally identified according to 
the capability of the compound to promote the GAG content of the 
media (DMMB readouts) normalized by the cellular activity (MTT 
readouts).
RESULTS:
From the primary HTS, the top 950 chemical compounds enhanced 
DMMB readouts from 4.5 to 50%, compared with the unperturbed
control. In the secondary HTS, 125 out of these 950 compounds 
retained the ability to produce over a 4.5% increment in DMMB 
readouts.  Figure 1 shows the prioritized DMMB result, together with 
the corresponding MTT result. Negligible changes in the MTT assay 
were observed with 297 chemical compounds; the MTT readouts were 
within ± one standard deviation from the medium control. Out of these 
297 compounds, the top 5 gave DMMB readouts, which were
normalized to their corresponding MTT values, ranging from 7.0 ± 1.3 
% to 19.0 ± 2.2 % (Fig. 2); they are regarded as positive hits for further
investigation. 
DISCUSSION:
The primary HTS was performed to exclude compounds that do not
promote GAG production or may reduce cellular metabolic activities.
However, inherent inaccuracies in compound transfer by the liquid 
handling platform in the primary screening may result in false-positives.
Instead of identifying positive hits from the primary HTS, a secondary 
screening with manual pipetting was performed to validate the effects of 
the compounds.
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Fig. 1. Normalized assay readouts of 950 chemical compounds.  and 
represent the result of DMMB and MTT assay vs. unperturbed control;
- and - refer to one standard deviation above and below (±) the MTT 
control, respectively.)
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Fig. 2. The percentage increase of 
GAG content, normalized with cell 
activity (i.e., DMMB readouts 
normalized with the MTT readouts),
of positive hits compared with the 
unperturbed control.
The secondary HTS suggests 
that there are chemical 
compounds capable of 
modulating the proteoglycan 
metabolism of chondrocytes 
without significant alteration 
of global metabolism or cell 
proliferation. In the future,
the top 5 hits will be validated 
using human chondrocytes 
and kinetic studies will be 
carried out to determine the
median effective 
concentrations to evaluate 
their efficacies. Gene 
expression profiling will be 
followed to investigate the 
genes involved for their 
action.
Our data suggest that chemical compounds can be potentially 
effective in maintaining or arresting the reduction of the proteoglycan 
content in cartilage. A further understanding of the affect of these
compounds on chondrocytes will facilitate the selection of candidates for 
animal model studies, as well as targets for future development of 
orally-administrated drugs for treating OA. These compounds may also 
help to identify interacting proteins that will facilitate the dissection of 
the molecular pathways relevant to GAG and/or proteoglycan 
metabolism, as well as the lesion process of cartilage.
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